Novo Nordisk the company behind the weight loss drug Wegovy posted stronger-than-expected net profit but trimmed its full-year sales growth forecast due to softer Wegovy sales. It now expects 2025 sales growth of 13% to 21% at constant exchange rates, down from the prior 16% to 24% range projected in February.